Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 20/20 | 0.51 |
| ▸ | JAK2 | O60674 | 19/20 | 0.51 |
| ▸ | JAK1 | P23458 | 19/20 | 0.51 |
| ▸ | JAK3 | P52333 | 5/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | STAT1 | P42224 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29567036 | 0.83 | JAK2 (0.55) | TYK2JAK2JAK1JAK3KDR | |
| SCHEMBL22856256 | 0.83 | JAK2 (0.55) | TYK2JAK2JAK1JAK3KDR | |
| Hydrochloric Acid SCHEMBL29414166 | 0.82 | JAK2 (0.54) | TYK2JAK2JAK1JAK3KDR | |
| SCHEMBL22856006 | 0.76 | JAK2 (0.56) | TYK2JAK2JAK1JAK3KDR | |
| SCHEMBL22855940 | 0.75 | JAK2 (0.67) | TYK2JAK2JAK1JAK3KDR | |
| SCHEMBL22856028 | 0.75 | JAK2 (0.57) | TYK2JAK2JAK1JAK3 | |
| SCHEMBL22856007 | 0.75 | JAK2 (0.57) | TYK2JAK2JAK1JAK3 | |
| SCHEMBL23276883 | 0.75 | JAK2 (0.57) | TYK2JAK2JAK1JAK3 | |
| SCHEMBL23276886 | 0.75 | JAK2 (0.57) | TYK2JAK2JAK1JAK3 | |
| SCHEMBL23277023 | 0.75 | JAK2 (0.57) | TYK2JAK2JAK1JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12448382-B2 | Heterocyclic compounds for mediating tyrosine kinase 2 activity | GUANGZHOU INNOCARE PHARMA TECH CO. LTD. (CN) | 2025-10-21 | — | — | US | disclosed |
| US-20220112200-A1 | HETEROCYCLIC COMPOUNDS FOR MEDIATING TYROSINE KINASE 2 ACTIVITY | GUANGZHOU INNOCARE PHARMA TECH CO., LTD. (CN) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220112200-A1 | HETEROCYCLIC COMPOUNDS FOR MEDIATING TYROSINE KINASE 2 ACTIVITY | TYK2, JAK2, JAK1 | TYK2 1/4885JAK2 2/4885JAK1 3/4885 |
| US-12448382-B2 | Heterocyclic compounds for mediating tyrosine kinase 2 activity | TYK2, JAK2, JAK1 | TYK2 1/4885JAK2 2/4885JAK1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.